<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00888654</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000641168</org_study_id>
    <secondary_id>P30CA022453</secondary_id>
    <secondary_id>WSU-2007-128</secondary_id>
    <nct_id>NCT00888654</nct_id>
  </id_info>
  <brief_title>Diindolylmethane in Treating Patients With Stage I or Stage II Prostate Cancer Undergoing Radical Prostatectomy</brief_title>
  <official_title>Phase II Trial of B-DIM (DIM: 3,3 Diindolylmethane) on Intermediate Endpoint Biomarkers in Patients With Prostate Cancer Who Are Undergoing Prostatectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Barbara Ann Karmanos Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Barbara Ann Karmanos Cancer Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: The use of diindolylmethane, a substance found in cruciferous vegetables, may slow
      the growth of tumor cells.

      PURPOSE: This phase II trial is studying how well diindolylmethane works in treating patients
      with stage I or stage II prostate cancer undergoing radical prostatectomy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To measure the level of diindolylmethane in prostate tissue after treatment with oral
           microencapsulated diindolylmethane (B-DIM) in patients with stage I or II adenocarcinoma
           of the prostate undergoing radical prostatectomy.

      Secondary

        -  To measure serum biomarkers (e.g., total PSA, serum testosterone, and diindolylmethane
           levels) pre- and post-treatment with B-DIM.

        -  To measure tissue biomarkers (e.g., androgen receptor, NF-κB, and PSA) pre- and
           post-treatment with B-DIM.

      OUTLINE: This is a multicenter study.

      Patients receive oral microencapsulated diindolylmethane (B-DIM) twice daily for 14-72 days
      in the absence of disease progression or unacceptable toxicity. Patients then undergo radical
      prostatectomy 1 day after the last dose of B-DIM.

      Patients undergo blood and tissue sample collection for correlative laboratory studies. Blood
      samples are analyzed for serum PSA, testosterone, and diindolylmethane levels by high
      performance liquid chromatography and tandem mass spectrometry (LC-MS/MS). Tissue samples are
      analyzed for diindolylmethane concentration by LC-MS/MS and for androgen receptor, activated
      NF-κB (p65 antibody), and PSA expression by IHC.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Level of Diindolylmethane in Prostate Tissue After Treatment</measure>
    <time_frame>Within the first 24 months after radical prostatectomy.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum Levels of PSA, Testosterone, and Diindolylmethane</measure>
    <time_frame>Pre and post radical prostatectomy</time_frame>
    <description>Serum levels of PSA, testosterone, and diindolylmethane (DIM)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of Androgen Receptor in Prostate Tissue</measure>
    <time_frame>Pre and post radical prostatectomy</time_frame>
    <description>Levels of androgen receptor in prostate tissue as measured by AR score (intensity x % cells stained), higher scores indicate higher levels of androgen receptor in prostate tissue.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>B-Dim, Radical Prosatectomy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>B-DIM 225 mg orally twice daily x 14-72 days (based on scheduling of surgery)
Radical Prostatectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>B-Dim</intervention_name>
    <description>B-DIM 225 mg orally twice daily x 14-72 days (based on scheduling of surgery)</description>
    <arm_group_label>B-Dim, Radical Prosatectomy</arm_group_label>
    <other_name>3,3'-Diindolylmethane</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Radical Prosatectomy</intervention_name>
    <arm_group_label>B-Dim, Radical Prosatectomy</arm_group_label>
    <other_name>therapeutic conventional surgery</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically or cytologically confirmed adenocarcinoma of the prostate

               -  Stage I or II (T1-T2 a, b, or c) disease

               -  Disease confined to the prostate by clinical judgment of the surgeon

          -  Deemed an appropriate candidate for surgery by clinical judgment of the surgeon

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-2

          -  ANC ≥ 1,500/mm³

          -  Platelet count ≥ 100,000/mm³

          -  Hemoglobin ≥ 8.0 g/dL

          -  Total bilirubin ≤ 1.5 times upper limit of normal (ULN)

          -  AST and/or ALT ≤ 2.5 times ULN if alkaline phosphatase normal OR alkaline phosphatase
             ≤ 4 times ULN if AST and/or ALT normal

          -  Serum creatinine ≤ 2.0 mg/dL

          -  No history of allergic reactions attributed to compounds of similar chemical or
             biological composition to oral microencapsulated diindolylmethane

          -  No concurrent uncontrolled illness including, but not limited to, any of the
             following:

               -  Ongoing or active infection

               -  Symptomatic congestive hart failure

               -  Unstable angina pectoris

               -  Cardiac arrhythmia

               -  Psychiatric illness or social situation that would limit compliance with study
                  requirements

        PRIOR CONCURRENT THERAPY:

          -  No prior chemotherapy, hormonal therapy, brachytherapy, cryotherapy, external beam
             radiotherapy, or other therapy for prostate cancer

          -  No concurrent micronutrient supplements or dietary soy products

          -  No concurrent systemic therapy for any other cancer

          -  No concurrent p450 inducers or inhibitors (e.g., carbamazepine, clarithromycin,
             fluconazole, fosphenytoin, itraconazole, ketoconazole, phenobarbital, phenytoin,
             rifabutin, or rifampin)

          -  No concurrent finasteride or dutasteride

          -  No other concurrent investigational or commercial agents or therapies for the
             malignancy
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elisabeth I. Heath, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Barbara Ann Karmanos Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Barbara Ann Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201-1379</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Josephine Ford Cancer Center at Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://cancer.gov/clinicaltrials</url>
    <description>Clinical trial summary from the National Cancer Institute's PDQ® database</description>
  </link>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 24, 2009</study_first_submitted>
  <study_first_submitted_qc>April 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2009</study_first_posted>
  <results_first_submitted>March 23, 2015</results_first_submitted>
  <results_first_submitted_qc>March 23, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 30, 2015</results_first_posted>
  <last_update_submitted>March 14, 2018</last_update_submitted>
  <last_update_submitted_qc>March 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Barbara Ann Karmanos Cancer Institute</investigator_affiliation>
    <investigator_full_name>Elisabeth Heath</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>adenocarcinoma of the prostate</keyword>
  <keyword>stage I prostate cancer</keyword>
  <keyword>stage II prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>3,3'-diindolylmethane</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>B-Dim, Radical Prosatectomy</title>
          <description>B-DIM 225 mg orally twice daily x 14-72 days (based on scheduling of surgery)
Radical Prostatectomy
B-Dim: B-DIM 225 mg orally twice daily x 14-72 days (based on scheduling of surgery)
Radical Prosatectomy</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Problems swallowing oral meds.</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not enough oral meds before surgery</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Surgery aborted</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Inelig. due to contraindication of med</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Change in surg date</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Stopped meds due to headaches</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>B-Dim, Radical Prosatectomy</title>
          <description>B-DIM 225 mg orally twice daily x 14-72 days (based on scheduling of surgery)
Radical Prostatectomy
B-Dim: B-DIM 225 mg orally twice daily x 14-72 days (based on scheduling of surgery)
Radical Prosatectomy</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="41"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58" lower_limit="20" upper_limit="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Level of Diindolylmethane in Prostate Tissue After Treatment</title>
        <time_frame>Within the first 24 months after radical prostatectomy.</time_frame>
        <population>Patients that were eligible, evaluable, and compliant</population>
        <group_list>
          <group group_id="O1">
            <title>B-Dim, Radical Prosatectomy</title>
            <description>B-DIM 225 mg orally twice daily x 14-72 days (based on scheduling of surgery)
Radical Prostatectomy
B-Dim: B-DIM 225 mg orally twice daily x 14-72 days (based on scheduling of surgery)
Radical Prosatectomy</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Level of Diindolylmethane in Prostate Tissue After Treatment</title>
          <population>Patients that were eligible, evaluable, and compliant</population>
          <units>ng/g</units>
          <param>Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.2" lower_limit="10.6" upper_limit="17.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Levels of PSA, Testosterone, and Diindolylmethane</title>
        <description>Serum levels of PSA, testosterone, and diindolylmethane (DIM)</description>
        <time_frame>Pre and post radical prostatectomy</time_frame>
        <population>All enrolled patients except for one patient who was deemed ineligible due to a disallowed concomitant medication and for one patient whose prostatectomy was cancelled because of adhesions found at the time of surgery.</population>
        <group_list>
          <group group_id="O1">
            <title>B-Dim, Radical Prosatectomy</title>
            <description>B-DIM 225 mg orally twice daily x 14-72 days (based on scheduling of surgery)
Radical Prostatectomy
B-Dim: B-DIM 225 mg orally twice daily x 14-72 days (based on scheduling of surgery)
Radical Prosatectomy</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Levels of PSA, Testosterone, and Diindolylmethane</title>
          <description>Serum levels of PSA, testosterone, and diindolylmethane (DIM)</description>
          <population>All enrolled patients except for one patient who was deemed ineligible due to a disallowed concomitant medication and for one patient whose prostatectomy was cancelled because of adhesions found at the time of surgery.</population>
          <units>ng/ml</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-treatment PSA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.4" lower_limit="2.1" upper_limit="29.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-treatment PSA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8" lower_limit="2.6" upper_limit="28.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-treatment Testosterone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="301" lower_limit="77" upper_limit="608"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-treatment Testosterone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="388" lower_limit="110" upper_limit="686"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-treatment DIM</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-treatment DIM</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5" lower_limit="0.0" upper_limit="24.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Levels of Androgen Receptor in Prostate Tissue</title>
        <description>Levels of androgen receptor in prostate tissue as measured by AR score (intensity x % cells stained), higher scores indicate higher levels of androgen receptor in prostate tissue.</description>
        <time_frame>Pre and post radical prostatectomy</time_frame>
        <population>All enrolled patients except for one patient who was deemed ineligible due to a disallowed concomitant medication and for one patient whose prostatectomy was cancelled because of adhesions found at the time of surgery.</population>
        <group_list>
          <group group_id="O1">
            <title>B-Dim, Radical Prosatectomy</title>
            <description>B-DIM 225 mg orally twice daily x 14-72 days (based on scheduling of surgery)
Radical Prostatectomy
B-Dim: B-DIM 225 mg orally twice daily x 14-72 days (based on scheduling of surgery)
Radical Prosatectomy</description>
          </group>
        </group_list>
        <measure>
          <title>Levels of Androgen Receptor in Prostate Tissue</title>
          <description>Levels of androgen receptor in prostate tissue as measured by AR score (intensity x % cells stained), higher scores indicate higher levels of androgen receptor in prostate tissue.</description>
          <population>All enrolled patients except for one patient who was deemed ineligible due to a disallowed concomitant medication and for one patient whose prostatectomy was cancelled because of adhesions found at the time of surgery.</population>
          <units>AR score (intensity x % cells stained)</units>
          <param>Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-BR-DIM Androgen Receptor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="278" lower_limit="263" upper_limit="293"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-BR-DIM Androgen Receptor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="245" lower_limit="227" upper_limit="263"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>B-Dim, Radical Prosatectomy</title>
          <description>B-DIM 225 mg orally twice daily x 14-72 days (based on scheduling of surgery)
Radical Prostatectomy
B-Dim: B-DIM 225 mg orally twice daily x 14-72 days (based on scheduling of surgery)
Radical Prosatectomy</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>There were no significant limitations.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Elisabeth Heath, M.D.</name_or_title>
      <organization>Barbara Ann Karmanos Cancer Institute</organization>
      <phone>313-576-8715</phone>
      <email>heathe@karmanos.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

